H.C. Wainwright reiterated Buy on Eton Pharmaceuticals stock

Published on 10/14/2026 at 00:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H.C. Wainwright kept USD 70.00 target October 1, 2026. Eton Pharmaceuticals stock had USD 37.59 million revenue in its June quarter, up 99.00 percent.

Commercial expansion and valuation

H.C. Wainwright reiterated its Buy rating and USD 70.00 target on October 1, 2026.
Eton Pharmaceuticals launched IMPAVIDO with exclusive U.S. commercialization rights on September 28, 2026.
Eton Pharmaceuticals had eleven commercial rare disease products on September 28, 2026.
The company had a USD 1.5 billion market capitalization as of October 13, 2026.

ETON, US29772L1089, Illustration mit AI erstellt.

Eton Pharmaceuticals stock (ISIN US29772L1089) was the subject of a Buy reiteration by Markets Insider on October 1, 2026, when H.C. Wainwright kept a USD 70.00 price target. The analyst action gives the rare disease specialist a fresh valuation reference after a strong second quarter.

Three dated company developments

On August 13, 2026, Eton Pharmaceuticals reported second-quarter 2026 product sales of USD 37.60 million, up 99.00 percent from the second quarter of 2025, alongside fully diluted GAAP earnings per share of USD 0.35 and non-GAAP fully diluted earnings per share of USD 0.43, according to Eton Pharmaceuticals. On September 28, 2026, GlobeNewswire reported that Eton launched IMPAVIDO in the United States with exclusive commercialization rights and expanded patient support.

Revenue growth raises expectations

The second-quarter sales figure was paired with higher full-year 2026 revenue guidance of more than USD 145.00 million and an adjusted EBITDA margin target of at least 35.00 percent, according to Eton Pharmaceuticals. The comparison matters because second-quarter product sales were USD 18.90 million in the prior-year period, making the latest growth rate a key test of whether new launches can support operating leverage.

What does IMPAVIDO add?

IMPAVIDO expands Eton's commercial platform into an antileishmanial treatment while using Eton Cares support and Anovo Specialty Pharmacy distribution. The September 28, 2026 release listed eleven commercial rare disease products and five additional late-stage product candidates, but it also described pregnancy-related fetal-harm risks and monitoring requirements for the new treatment.

Market value sets the frame

Eton Pharmaceuticals had a USD 1.5 billion market capitalization as of October 13, 2026. Against that valuation, the USD 70.00 analyst target and the more than USD 145.00 million 2026 revenue outlook make commercial execution the central measure for the stock after the IMPAVIDO launch.